MedWatch

Pfizer acquires commercial rights to Biohaven migraine drug outside the US

Biohaven, which is the firm behind the migraine tablet Nurtec, has allied itself with Pfizer in a strategic collaboration about the commercialization of the drug outside the US.

Photo: Dado Ruvic/REUTERS / X02714

Pfizer has acquired the commercial rights of the US-based biotech company Biohaven's migraine drug Nurtec outside of the US, it reports in a press release.

Nurtec is the first tablet-based treatment of its drug class known as CGRP inhibitors to be approved both as a preventive and acute treatment of episodic migraines. Most other CGRP inhibitors are administered by injection, with the exception of Lundbeck's Vyepti that is administered as an intravenous (IV) infusion in hospitals. Biohaven's Nurtec has another tablet competitor in the drug Abbvie's Ubrelvy, but the latter has only been approved as an acute treatment for migraines.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs